Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 20;23(3):1109.
doi: 10.3390/ijms23031109.

Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers

Andrei Havasi  1   2   3 , Daniel Sur  1   2 , Simona Sorana Cainap  4 , Cristian-Virgil Lungulescu  5 , Laura-Ioana Gavrilas  6 , Calin Cainap  1   2 , Catalin Vlad  7   8 , Ovidiu Balacescu  2   9
Affiliations
Review

Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers

Andrei Havasi et al. Int J Mol Sci. .

Abstract

Pancreatic neuroendocrine tumors (PanNETs) are rare tumors; however, their incidence greatly increases with age, and they occur more frequently among the elderly. They represent 5% of all pancreatic tumors, and despite the fact that low-grade tumors often have an indolent evolution, they portend a poor prognosis in an advanced stages and undifferentiated tumors. Additionally, functional pancreatic neuroendocrine tumors greatly impact quality of life due to the various clinical syndromes that result from abnormal hormonal secretion. With limited therapeutic and diagnostic options, patient stratification and selection of optimal therapeutic strategies should be the main focus. Modest improvements in the management of pancreatic neuroendocrine tumors have been achieved in the last years. Therefore, it is imperative to find new biomarkers and therapeutic strategies to improve patient survival and quality of life, limiting the disease burden. MicroRNAs (miRNAs) are small endogenous molecules that modulate the expression of thousands of genes and control numerous critical processes involved in tumor development and progression. New data also suggest the implication of miRNAs in treatment resistance and their potential as prognostic or diagnostic biomarkers and therapeutic targets. In this review, we discusses the current and new challenges in the management of PanNETs, including genetic and epigenetic approaches. Furthermore, we summarize the available data on miRNAs as potential prognostic, predictive, or diagnostic biomarkers and discuss their function as future therapeutic targets.

Keywords: MicroRNAs; biomarkers; diagnosis; genetic; pancreatic neuroendocrine tumors (PanNETs); prognosis; therapeutic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic illustration of microRNA biogenesis.
Figure 2
Figure 2
Schematic illustration of the effect of miRNAs as diagnostic, prognostic, and therapeutic biomarkers in PanNETs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee M.R., Harris C., Baeg K.J., Aronson A., Wisnivesky J.P., Kim M.K. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. Clin. Gastroenterol. Hepatol. 2019;17:2212–2217.e1. doi: 10.1016/j.cgh.2018.12.017. - DOI - PubMed
    1. Choe J., Kim K.W., Kim H.J., Kim D.W., Kim K.P., Hong S.-M., Ryu J.-S., Tirumani S.H., Krajewski K., Ramaiya N. What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms? Korean J. Radiol. 2019;20:5. doi: 10.3348/kjr.2018.0040. - DOI - PMC - PubMed
    1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 2008;19:1727–1733. doi: 10.1093/annonc/mdn351. - DOI - PMC - PubMed
    1. Lesén E., Granfeldt D., Houchard A., Berthon A., Dinet J., Gabriel S., Björstad Å., Björholt I., Elf A.K., Johanson V. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden—A population-based register-linkage study. Eur. J. Cancer Care. 2019;28:e12983. doi: 10.1111/ecc.12983. - DOI - PMC - PubMed